-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A successful conclusion | BIFT-CGT 2022 China Biopharmaceutical Innovation and Frontier Technology Summit & Cell and Gene Therapy Innovation Conference
BIFT-CGT 2022 China Biopharmaceutical Innovation and Frontier Technology Summit & Cell and Gene Therapy Innovation Conference, hosted by Haohui Consulting, co-hosted by Medici Biopharmaceutical, and supported by the US-Chinese Medicine Development Association, American Chinese Biomedical Technology, Shanghai Biomedical Industry Promotion Center and other institutions, was successfully held at Crowne Plaza Shanghai St.
Noah on October 20-21!
Noah on October 20-21!
The conference is divided into three special forums, including the first novel antibody development forum, the 5th biopharmaceutical innovation and frontier technology forum, and the 4th cell and gene therapy innovation conference
.
A total of 70 industry leaders gave wonderful speeches, attracting nearly 800 industry colleagues to sign up
.
.
A total of 70 industry leaders gave wonderful speeches, attracting nearly 800 industry colleagues to sign up
.
70 experts from Huaaotai Biotech, Yourui Biologics, Pioneer Pharmaceutical, Boji Biologics, Innovent Biologics, Qiyue Biologics, Huaiyue Biologics, Harbour Biologics, Gaipu Biologics, China Resources Biologics, Linlu Pharmaceutical, Mabwell, Vanshi Biologics, Baiquan Biologics, Dongyao Pharmaceutical, Lepu Biologics, JW Therapeutics, Fosun Kate, Bangyao Biologics, Yimufeng, Aqua Biologics, Keji Biologics and other outstanding representatives attended the event
。 With the theme of "From Laboratory to Industrialization, Accelerate the Pace of New Drug Launch", explore more possibilities of cooperation at the BIFT-CGT 2022 conference site, and empower new drug R&D and innovation based on patient needs!
Session 1: Novel Antibody Development Forum
Host guest
Shuangqing Peng, Chief Scientist, Medici Biomedical
Sharing topic: Current situation and challenges of biopharmaceutical research in China
Xiangyang Zhu, General Manager, Huaaotai Biotech
Sharing topic: Precision targeting and holistic immune activation technologies: the future of immuno-oncology
Jian Ni, CEO, Uniray Biologics
Sharing topic: development of bispecific antibody drugs based on ALK1 targets
Jianfei Yang, Vice President/Biopharmaceuticals, Pioneer Pharmaceutical
Panel discussion: Development opportunities and future of innovative bispecific antibodies
From left to right:
Shuangqing Peng, Chief Scientist, Medici Biomedical
Xiangyang Zhu, General Manager, Huaaotai Biotech
Jianfei Yang, Vice President/Biopharmaceuticals, Pioneer Pharmaceutical
Haizhou Zhang, CEO, Boji Biotechnology
Sun Hongyan, Deputy Director of Functional Efficacy Center, Ji Zhi Yao Kang
Session 2: Cell and Gene Therapy Innovation Conference
Sharing topic: innovation, R&D progress and challenges in the field of cell therapy
Zhao Jinghua, Chief Medical Officer, Fosun Kate
Sharing topic: development and clinical application of non-viral fixed-point integrated CAR-T technology
Zhang Xiqin, Vice President of R&D, BangYao Biologics
Sharing topic: The road of CAR-T cell therapy products from R&D to industrialization
Qingshan Shen, Vice President of Quality and Production Operations, Yi Mufeng
Sharing topic: CD7 CAR-T therapy in the development and transformation of T cell hematological tumors
Hongsheng Zhang, Founder, Yako Biologics
Session 3: Biopharmaceutical Innovation and Frontier Technology Forum
Sharing topic: The present and future of biopharmaceutical process technology
Yang Jianguo, Chief Strategy Officer, CR Biopharmaceutical
Sharing topic: The future of biopharmaceutical digital factory design and quality control
Xun Liu, CTO, Linglu Pharmaceutical
Sharing topic: design and implementation strategy of large-scale production plant for antibody drugs
Hua Ni, Vice President, Mabwell
Sharing topic: Solving the challenges of the production process with the natural IgG structure bispecific antibody platform
Kelan Chen, Executive Director, Vansys Biotech
At this point, the two-day BIFT-CGT 2022 China Biopharmaceutical Innovation and Frontier Technology Summit and Cell and Gene Therapy Innovation Conference has come to a successful end
.
How-Hui Consulting hopes to continue to work closely with senior experts, outstanding enterprises and institutions in the industry, provide cutting-edge information in the industry, explore industry trends, and help China's biopharmaceutical innovation and cooperation
.
.
How-Hui Consulting hopes to continue to work closely with senior experts, outstanding enterprises and institutions in the industry, provide cutting-edge information in the industry, explore industry trends, and help China's biopharmaceutical innovation and cooperation
.
In recent years, the development of biologics has been extremely rapid, and biologics such as antibodies, ADCs, and vaccines are playing an increasingly important role
in the treatment of many serious, chronic, currently untreated diseases.
Cell and gene therapy has revolutionized the treatment of
serious and chronic diseases such as cancer and certain rare diseases.
In order to promote oncolytic viruses to the clinic and promote oncolytic virus drugs to benefit more patients as soon as possible, the "BIFT Biopharmaceutical Innovation and Frontier Technology Summit" has been successfully held for 5 sessions since 2016, discussing the design, research and development, process technology, clinical application and supervision of antibody and cell therapy drugs, which has aroused great repercussions
from academia and industry.
in the treatment of many serious, chronic, currently untreated diseases.
Cell and gene therapy has revolutionized the treatment of
serious and chronic diseases such as cancer and certain rare diseases.
In order to promote oncolytic viruses to the clinic and promote oncolytic virus drugs to benefit more patients as soon as possible, the "BIFT Biopharmaceutical Innovation and Frontier Technology Summit" has been successfully held for 5 sessions since 2016, discussing the design, research and development, process technology, clinical application and supervision of antibody and cell therapy drugs, which has aroused great repercussions
from academia and industry.
We will meet again next year, so stay tuned for more exciting BIFT-CGT 2023!
Phone:+86 150 0218 0039
Email: enquiry@gecgroup.
com.
cn
com.
cn
